Abstract:Objective:To clarify the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant on the performance of existing molecular diagnostic assays, and investigate the detection ability of clinical laboratories across China.Methods:The first nationwide external quality assessment (EQA) for molecular detection of Delta variant was carried out based on the non-infectious phage virus-like particles samples, which were prepared by genetic engineering methods and distributed to 8 488 laboratories nationwide. The EQA panel was composed of three Delta variant samples (7.5×10 2, 1.5×10 3 and 6.0×10 3 copies/ml), one non-variant weak positive sample and one negative sample. The percentage of agreement (PA) of Delta variant samples with different concentration, the PA of Delta variant and non-variant samples with 7.5×10 2 copies/ml, the PA of assays used by more than 100 laboratories for Delta variant samples with different concentration and the PA of Delta variant and non-variant samples with 7.5×10 2 copies/ml were calculated and analyzed. Results:The data from 8 127 laboratories were available for evaluation. The testing capability of 98.77% (8 027/8 127) of the participating laboratories was found to be competent in reporting correct results for all samples. The overall percentage of agreement (OPA), negative percentage of agreement (NPA) and positive percentage of agreement (PPA) of the samples were 99.64% (40 490/40 635), 99.73% (8 105/8 127), 99.62% (32 385/32 508), respectively. With the decrease of the concentration of the samples, the PPA of Delta variant samples decreased. The PPAs were 99.41% and 99.51% for Delta variant and non-variant samples with 7.5×10 2 copies/ml, respectively, with no statistical difference ( P=0.392). The OPA, NPA and PPA of the assays used by more than 100 laboratories were all greater than 98%, and no statistical difference of the PPAs was identified between Delta variant and non-variant samples with 7.5×10 2 copies/ml ( P>0.05). Conclusions:Delta variant fails to impair the performance of current molecular diagnostic assays in China. The clinical laboratories have the same detection capabilities for Delta variant and non-variant samples. However, in certain laboratories, further improvement is required to ensure the accurate detection of weak positive samples.

External Quality Assessment Program for SARS‐COV‐2 Molecular Detection in Pakistan

Evaluation of Sensitivity and Specificity of Three Commercial Real-Time Quantitative Polymerase Chain Reaction Kits for Detecting SARS-CoV-2 in Bangladesh

External Quality Assessment (EQA) for SARS-CoV-2 RNA Point-of-Care Testing in Primary Healthcare Services: Analytical Performance over Seven EQA Cycles

The development and implementation of a proficiency testing program for SARS-CoV-2 using dried tube specimens in resource-limited countries

Impact of COVID-19 on quality checks of solid tumor molecular diagnostic testing-A surveillance by EQAS provider in India

SITUATION OF CORONAVIRUS IN PAKISTAN REGARDING DIAGNOSIS, LAB FACILITIES, MEDICAL EQUIPMENTS, ISOLATION WARDS IN HOSPITALS AND ITS COMPARISON WITH WORLD

External quality assessments for SARS-CoV-2 genome detection in Austria

SARS-CoV-2 variants and genomic surveillance in the low-resource north-west region of Pakistan

High quality of SARS-CoV-2 molecular diagnostics in a diverse laboratory landscape through supported benchmark testing and External Quality Assessment

Disparities in age and gender-specific SARS-CoV-2 diagnostic testing trends: a retrospective study from Pakistan

Guidelines and Safety Considerations in the Laboratory Diagnosis of SARS-CoV-2 Infection: A Prerequisite Study for Health Professionals

The WHO AFRO external quality assessment programme (EQAP): Linking laboratory networks through EQA programmes

Insight into Prognostics, Diagnostics, and Management Strategies for SARS CoV-2

Syndromic approach to SARS-CoV-2 detection using QIAstat-Dx SARS-CoV-2 panel from clinical samples

Indian microbiology EQAS registered laboratory's capacity building and infection control practices during the COVID-19 pandemic in India: Lessons learnt and gaps identified

National External Quality Assessment for Molecular Detection of Severe Acute Respiratory Syndrome Coronavirus 2 Delta Variant

Application Experience of a Rapid Nucleic Acid Detection System for COVID-19

Longitudinal analysis of 20 Years of external quality assurance schemes for PCR/NAAT-based bacterial genome detection in diagnostic testing

Results of a European-Wide External Quality Assessment (EQA) Scheme for Serological Detection of Anti-SARS-CoV-2 (CoVimm)—Pitfalls of Routine Application

External quality assessment for molecular detection of Ureaplasma urealyticum in China

Genomic Epidemiology of SARS-CoV-2 in Pakistan.